期刊
GLIA
卷 59, 期 8, 页码 1155-1168出版社
WILEY
DOI: 10.1002/glia.21142
关键词
PDGF; EGFR; NF1; mouse models; glioma
资金
- NCI [R01 CA131313, U01 CA141556]
- Goldhirsh Foundation
- McDonnell Foundation [JSMF-220020206]
- CPRIT [RP 100782]
- ACS [117409]
- American Cancer Society and Seed Money from Cleveland Clinic Foundation [IRG-91-022-15]
The recently published comprehensive profiles of genomic alterations in glioma have led to a refinement in our understanding of the molecular events that underlie this cancer. Using state-of-the-art genomic tools, several laboratories have created and characterized accurate genetically engineered mouse models of glioma based on specific genetic alterations observed in human tumors. These in vivo brain tumor models faithfully recapitulate the histopathology, etiology, and biology of gliomas and provide an exceptional experimental system to discover novel therapeutic targets and test therapeutic agents. This review focuses on mouse models of glioma with a special emphasis on genetically engineered models developed around key genetic glioma signature mutations in the PDGFR, EGFR, and NF1 genes and pathways. The resulting animal models have provided insight into many fundamental and mechanistic facets of tumor initiation, maintenance and resistance to therapeutic intervention and will continue to do so in the future. (C) 2011 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据